Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6901 to 6915 of 7707 results

  1. Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]

    Discontinued [GID-TA10332]

    Technology appraisal guidance
    Discontinued

  2. Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]

    Discontinued [GID-TA10522]

    Technology appraisal guidance
    Discontinued

  3. Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]

    In development [GID-TA10589] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]

    In development [GID-TA10779] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. ALXN1840 for treating Wilson disease TS ID 9950

    In development [GID-TA11449] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]

    In development [GID-TA10822] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma [ID3940]

    Discontinued [GID-TA10830]

    Technology appraisal guidance
    Discontinued

  8. Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667]

    Discontinued [GID-TA10567]

    Technology appraisal guidance
    Discontinued

  9. Etrolizumab for previously treated moderately to severely active Crohn's disease [ID3965]

    Discontinued [GID-TA10870]

    Technology appraisal guidance
    Discontinued

  10. Durvalumab with chemoradiation for untreated locally advanced cervical cancer [ID5081]

    Discontinued [GID-TA10963]

    Technology appraisal guidance
    Discontinued

  11. Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930]

    Discontinued [GID-TA10811]

    Technology appraisal guidance
    Discontinued

  12. ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]

    In development [GID-TA10489] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]

    Discontinued [GID-TA10495]

    Technology appraisal guidance
    Discontinued

  14. Workplace health - older employees

    Discontinued [GID-PHG59]

    NICE guideline
    Discontinued

  15. DHT pilot: DECODE decision support system for the identification of dementia (Discontinued)

    Discontinued [GID-MT536]

    Medical technologies guidance
    Discontinued